Evaxion to present two-year clinical efficacy data from phase 2 trial with ai-designed personalized cancer vaccine evx-01 at the esmo congress 2025

Copenhagen, denmark, july 25, 2025 - evaxion a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound evx-01 at the european society for medical oncology (esmo) congress 2025 to be held in berlin, germany, from october 17-21, 2025.
EVAX Ratings Summary
EVAX Quant Ranking